I don't follow your train of thinking. The issue was a potential combination treatment for obesity and cardiovascular / metabolic disease, which are often comorbidities. Enbrel and Neulasta address unrelated indications.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”